Clinical diagnostics and healthcare company Alere today announced the European launch of the Alere i platform and Influenza A & B test, a molecular assay designed to detect and differentiate those viruses in less than 15 minutes.

The test and Alere i platform, which uses isothermal nucleic acid amplification technology to facilitate point-of-care testing, is now commercially available in Austria, France, Spain, Switzerland, Germany, Italy, and the UK. The test is not yet available in the US but is currently under regulatory review by the US Food and Drug Administration.